Is meperidine alive and well in the new millennium : evaluation of meperidine usage patterns and frequency of adverse drug reactions?
Patients using PCA meperidine are at particularly high risk of experiencing ADRs based on cumulative doses and duration of treatment. Adverse drug reactions were documented in approximately 14% of patients. Our results warrant restriction of PCA meperidine and evaluation of meperidine usage policies to improve pain management services and decrease the frequency of ADRs.
Since proinflammatory cytokines play a major role in the pathology of GvHD, their down-regulation post-ECP may produce a direct clinical benefit. The lowest number of IL2-, IFNgamma- and TNFalpha-expressing T cells occurred within the apoptotic population; however, Annexin V-negative T cells also demonstrated a marked reduction post-ECP. However, the lack of an increase in IL4 and IL10 expression indicates that this process was not a consequence of skewing toward a Th2 cytokine profile.